Skip to main content

Advertisement

SpringerLink
Log in

A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Introduction

Fluoropyrimidine plus platinum (FP)-based chemotherapy has been widely used as a first-line regimen for advanced or recurrent esophageal cancer, and taxanes have shown efficacy after FP-based chemotherapy, but there is no standard regimen for second-line chemotherapy (SLC). We retrospectively investigated the clinical features of taxane therapy in SLC for esophageal squamous cell carcinoma (ESCC).

Methods

The selection criteria were pathologically proven ESCC; advanced or recurrent disease previously treated with FP at our hospital; performance status (PS) 0–2; and adequate organ function. Docetaxel (DTX) was administered 3-weekly at 70 mg/m2. Paclitaxel (PTX) was administered at 100 mg/m2 weekly for 6 weeks, with 1 week’s rest.

Results

The analysis covered 163 patients from August 2006 to June 2012. Median age was 64 years (range 37–83: DTX group 132 patients and PTX group 31). Progression-free survival and median overall survival (OS) were 2.3 and 6.1 months, respectively, with PTX and 2.3 and 5.3 months with DTX. Response rates were 20.7 % for PTX and 5.9 % for DTX. The rate of grades 3–4 neutropenia was higher with DTX (32.6 %) than with PTX (16.1 %). Grade 3 febrile neutropenia was seen in 6.1 % of DTX recipients but in no PTX group. According to multivariate analyses of OS, PS 2, number of metastatic sites ≧2, and CRP ≧1 mg/dL were independent predictors of poor prognosis.

Conclusions

PTX and DTX were both effective in SLC for ESCC, but their toxicity profiles differed. In terms of febrile neutropenia, PTX seems more appropriate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30

    Article  PubMed  Google Scholar 

  2. Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90

    Article  PubMed  Google Scholar 

  3. Demographic statistics. Ministry of Health, Labour and Welfare, Japan, 2006

  4. Hayashi K, Ando N, Watanabe H et al (2001) Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) trial (JCOG9407). Jpn J Clin Oncol 31(9):419–423

    Article  CAS  PubMed  Google Scholar 

  5. Ilson DH (2003) Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev 29:525–532

    Article  PubMed  Google Scholar 

  6. Bleiberg H, Conroy T, Paillot B et al (1997) Randomized phase II study of cisplatin and 5-FU versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33:1216–1220

    Article  CAS  PubMed  Google Scholar 

  7. Vanhoefer U, Rougier P, Wilke H et al (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 18:2648–2657

    CAS  PubMed  Google Scholar 

  8. Muro K, Hamaguchi T, Ohtsu A et al (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 15(6):955–959

    Article  CAS  PubMed  Google Scholar 

  9. Kato K, Tahara M, Hironaka S et al (2011) A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 67(6):1265–1272

    Article  CAS  PubMed  Google Scholar 

  10. Heath EI, Urba S, Marshall J et al (2002) Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Investig New Drugs 20(1):95–99

    Article  CAS  Google Scholar 

  11. Anderson SE, O’Reilly EM, Kelsen DP et al (2003) Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer. Cancer Invest 21:512–516

    Article  CAS  PubMed  Google Scholar 

  12. Thallinger CMR, Raderer M, Hejna M (2011) Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol 29(35):4709–4714

    Article  CAS  PubMed  Google Scholar 

  13. Hirao M, Ando N, Tsujinaka T et al (2011) Influence of preoperative chemotherapy for advanced thoracic oesophageal squamous cell carcinoma on perioperative complications. Br J Surg 98(12):1735–1741

    Article  CAS  PubMed  Google Scholar 

  14. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241–2252

    Article  CAS  PubMed  Google Scholar 

  15. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  CAS  PubMed  Google Scholar 

  16. Cox DR (1972) Regression models and life-tables. J R Stat Soc B 34:187–202

    Google Scholar 

  17. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343–346

    Article  CAS  PubMed  Google Scholar 

  18. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  19. Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures. J R Stat Soc A 135(2):185–207

    Article  Google Scholar 

  20. Lorenzen S, Schuster T, Porschen R et al (2009) Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 20(10):1667–1673

    Article  CAS  PubMed  Google Scholar 

  21. Mizota A, Shitara K, Kondo C et al (2011) A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy. Oncology 81(3–4):237–242

    Article  CAS  PubMed  Google Scholar 

  22. Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359–1367

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Takenaka M, Iida H, Matsumoto S et al (2013) Successful treatment by adding duloxetine to pregabalin for peripheral neuropathy induced by paclitaxel. Am J Hosp Palliat Care 30(7):734–736

    Article  PubMed  Google Scholar 

  24. Caraceni A, Zecca E, Bonezzi C et al (2004) Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 22(14):2909–2917

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None of the authors has a conflict of interests.

Author information

Authors and Affiliations

  1. Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Tsuyoshi Shirakawa, Ken Kato, Akiko Nishikawa, Ryoichi Sawada, Naoki Takahashi, Hirokazu Shoji, Yusuke Sasaki, Yoshitaka Honma, Satoru Iwasa, Atsuo Takashima, Natsuko Okita, Tetsuya Hamaguchi, Yasuhide Yamada & Yasuhiro Shimada

  2. Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, 3-1-1, Notame, Minami-ku, Fukuoka-shi, 811-1395, Japan

    Tsuyoshi Shirakawa

  3. Clinical Research Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8677, Japan

    Kengo Nagashima

Authors
  1. Tsuyoshi Shirakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ken Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kengo Nagashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akiko Nishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryoichi Sawada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Naoki Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hirokazu Shoji
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yusuke Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshitaka Honma
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Satoru Iwasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Atsuo Takashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Natsuko Okita
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tetsuya Hamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Yasuhide Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yasuhiro Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ken Kato.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shirakawa, T., Kato, K., Nagashima, K. et al. A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy. Cancer Chemother Pharmacol 74, 1207–1215 (2014). https://doi.org/10.1007/s00280-014-2597-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-014-2597-3

Keywords

Search

Navigation